— ACTIV-6 trial shows no time-to-recovery benefit with anti-parasitic in mild-to-moderate disease
by Ed Susman
There were no differences in relief from mild-to-moderate COVID-19 symptoms for patients on ivermectin versus placebo, according to the ongoing ACTIV-6 trial.
Among >1,000 vaccinated and unvaccinated patients, the median time to recovery was 12 days for those in the ivermectin group and 13 days in the placebo group, reported Matthew McCarthy, MD, of Weill Cornell Medicine in New York City, at IDWeek.
As a result, the hazard ratio for improvement in time to recovery was 1.07 (95% credible interval 0.96-1.17, posterior P=0.91), McCarthy and colleagues stated in JAMA, where the results were simultaneously published.